TREAT(_Transdermal _Relief: _Evaluating _Allergy _Topicals for Perennial Allergic Rhinitis)
TREAT is an IRB-approved observational study to evaluate patients’ experiences and/or perceptions of prescribed transdermal allergy medications to treat seasonal and perennial allergy symptoms.
Become a Study Investigator
To learn more about our TREAT study, please call our dedicated Healthcare Provider HelpDesk at
Thomas F. Smith, MD, FAAAAI, FACAAI, FAAP
Greater Austin Allergy, Asthma & Immunology, PLLC
Clinical Professor of Internal Medicine and Pediatrics
College of Medicine, Texas A&M Health Science Center
Round Rock, TX
Fellow of the American College of Allergy, Asthma, and Immunology
Joint Council of Allergy and Immunology, Texas Allergy and Immunology Society
Member, Expert Panel for Allergy of the Texas Medical Board
To evaluate patient perceptions of allergic rhinitis treatment with the use of topical formulations via a patient-reported survey.
TREAT evaluates patient experiences and responses to transdermal allergy treatment based on the widely used Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), developed to measure the functional problems (physical, emotional, social, and occupational) in patients suffering from seasonal or perennial rhinoconjuctivitis. It also evaluates based on the Quality of Life (QOL) for allergic rhinitis.
Our TREAT study is underway. We look forward to sharing data as soon as it is available.
TREAT Conference HighlightsMORE TREAT CONFERENCES
We look forward to sharing information regarding our TREAT study at the 2016 AAAAI Annual Meeting.